- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05774561
Papel das biópsias líquidas no monitoramento do tratamento do câncer associado ao HPV
Biópsias líquidas - uma possível ferramenta para monitoramento de tratamento e detecção precoce de recorrência em doenças associadas ao HPV
This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.
Visão geral do estudo
Status
Descrição detalhada
Although the cancers associated with human papillomavirus (HPV) infection are currently almost entirely preventable, a significant part of the Czech population suffers from these diseases. The most common HPV-associated cancers are cervical cancer (CC) and oropharyngeal cancer (OPC). In these, the severe problem is successful monitoring of the treatment effectiveness and early disease recurrence detection. It is, therefore, necessary to find a non-invasive method that could specifically and timely identify patients at risk of recurrence and thus enable patients with quality and less burdensome medical care. The use of liquid biopsies (LB), which the study focuses on, looks most promising.
This study is divided into two arms, with each arm including both prospective and retrospective parts. Into prospective parts will be enrolled only newly diagnosed CC/HSIL (high-grade cervical intraepithelial lesions) or OPC patients. In contrast, the retrospective part will enroll patients in post-treatment follow-up. In both study arms, fresh tumor tissues will be sampled from patients in prospective parts before treatment, and archived Formalin Fixed Paraffin Embedded (FFPE) tissue samples will be obtained from patients of retrospective parts.
Regarding the liquid biopsies, pre & post-treatment sampling of LB will be performed. Subsequently, regular sample acquisition will be performed during follow-up according to the standard medical practice in both prospective and retrospective parts. Oropharyngeal swabs, gargle lavage,exhaled breath condensate (EBC), and blood samples will be collected from OPC patients. Blood collection and self-sampling of cervicovaginal swabs will be performed in patients with CC/HSIL. All samples, excluding blood samples, will be tested for the presence of the most prevalent high-risk and low-risk HPV genotypes. The circulating tumor (ct) HPV DNA will be monitored in blood samples. Additionally, the mutation profile of the primary tumors will be examined in fresh and FFPE samples.
The dynamics of HPV DNA will be monitored throughout all follow-up samples and correlated with the obtained clinical data. A created panel of frequently altered genes will be used for alterations monitoring in liquid biopsies. In the final analysis of laboratory and clinical results, we assume a finding of a clinically usable algorithm that could predict the risk of disease recurrence for a particular patient.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Vladimira Koudelakova, MSc, Ph.D.
- Número de telefone: +420 585 632 089
- E-mail: vladimira.koudelakova@upol.cz
Estude backup de contato
- Nome: Marian Hajduch, MD., PhD.
- Número de telefone: +420 585 632 083
- E-mail: marian.hajduch@upol.cz
Locais de estudo
-
-
-
Olomouc, Tcheca, 77900
- Recrutamento
- University Hospital Olomouc
-
Contato:
- Marian Hajduch, MD, PhD.
- Número de telefone: +420 585 632 083
- E-mail: marian.hajduch@upol.cz
-
Contato:
- Vladimira Koudelakova, MSc., PhD.
- Número de telefone: +420 585 632 089
- E-mail: vladimira.koudelakova@upol.cz
-
Investigador principal:
- Radovan Pilka, prof. MD,PhD
-
Investigador principal:
- Richard Salzman, MD, PhD.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Oropharyngeal cancer patients, Cervical cancer patients
Descrição
Inclusion Criteria:
Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.
Exclusion Criteria:
No exclusion criteria are set.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: OTHER
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Arm A - Oropharyngeal cancer patients
In total, approx. 200 OPC cancer patients will be enrolled in the study Arm A, with both prospective and retrospective parts enrolling 100 OPC patients. The Arm A will enroll patients from the Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (gargle lavage, oropharyngeal smear, breath condensate, and blood sample) will be collected. Obtained samples will be tested by CE-IVD (device complies with European in vitro diagnostic Directive) marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 3 years and every 6 months for 2 years. |
Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians. |
|
Arm B - Cervical cancer patients
Into the study Arm B will be enrolled 80 patients with CC and 120 patients with HSIL, and 80 patients will be enrolled into the retrospective part. The Arm B will enroll patients from the Department of Gynecology and Obstetrics, University Hospital Olomouc. Pre-treatment primary samples of fresh or FFPE tissue samples will be collected. Liquid biopsies (cervicovaginal swab and blood sample) will be collected. Obtained samples will be tested by CE-IVD marked HPV diagnostic test. A laboratory developed digital droplet PCR assay will be used for ct HPV DNA detection. Sampling will be performed at pre & post treatment check-ups, and every 3 months for 2 years and every 6 months for 3 years. |
Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dynamics of HPV infection in cervical cancer patients during 4-year follow-up.
Prazo: 4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of HPV infection in oropharyngeal cancer patients during 4-year follow-up.
Prazo: 4 years
|
HPV-status in liquid biopsies collected during pre-treatment, post-treatment and follow-up check-ups. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in oropharyngeal cancer patients.
Prazo: 4 years
|
Correlation of plasmatic ct HPV DNA level with cancer patient´s prognosis. |
4 years
|
|
Dynamics of circulating tumor (ct) HPV DNA in cervical cancer patients
Prazo: 4 years
|
Correlation of plasmatic ct HPV DNA level with patient´s prognosis |
4 years
|
|
Analysis of the mutational landscape of oropharyngeal cancer cases.
Prazo: 4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
|
Analysis of the mutational landscape of cervical cancer cases.
Prazo: 4 years
|
Correlation of tumor mutational burden (TMB) with cancer patient´s prognosis. |
4 years
|
Colaboradores e Investigadores
Investigadores
- Diretor de estudo: Marian Hajduch, MD., PhD., IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças estomatognáticas
- Processos Patológicos
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Atributos da doença
- Infecções
- Doenças Virais
- Doenças uterinas
- Doenças Genitais Femininas
- Neoplasias de Cabeça e Pescoço
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por vírus de DNA
- Neoplasias Genitais Femininas
- Condições pré-cancerosas
- Doenças do colo do útero
- Doenças Otorrinolaringológicas
- Neoplasias uterinas
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Doenças Faríngeas
- Infecções por Vírus Tumorais
- Condições Patológicas, Sinais e Sintomas
- Neoplasias do colo uterino
- Infecções por Papilomavírus
- Displasia Cervical Uterina
- Neoplasias Orofaríngeas
- Técnicas de investigação
- Manipulação de amostras
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Técnicas citológicas
- Biópsia
- Citodiagnóstico
- Biópsia líquida
Outros números de identificação do estudo
- NU-23-03-00255
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .